Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.
| Drug | TSG | SLP (drug target) | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | # |
|---|---|---|---|---|---|---|---|---|---|---|
| sunitinib | EP300 | KIT | 7 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | EP300 | RET | 4 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | EP300 | KIT | 4 | |||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | EP300 | RET | 4 | |||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | EP300 | KIT | 4 | |||||||
| crizotinib | EP300 | ALK | 7 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | EP300 | ALK | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | EP300 | RET | 3 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | EP300 | KIT | 3 | |||||||
| futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan | EP300 | TOP1MT | 3 | |||||||
| lurbinectedin, irinotecan | EP300 | TOP1MT | 3 | |||||||
| nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone | EP300 | RXRB | 3 | |||||||
| pembrolizumab, belzutifan, lenvatinib | EP300 | RET | 3 | |||||||
| pembrolizumab, belzutifan, lenvatinib | EP300 | KIT | 3 | |||||||
| avapritinib | EP300 | KIT | 7 | |||||||
| pazopanib | EP300 | KIT | 7 | |||||||
| regorafenib | EP300 | RET | 7 | |||||||
| regorafenib | EP300 | KIT | 7 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | EP300 | ALK | 2 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | EP300 | RET | 2 | |||||||
| alectinib, stereotactic radiosurgery | EP300 | ALK | 2 | |||||||
| alvocidib, paclitaxel | EP300 | CDK9 | 2 | |||||||
| apatinib, irinotecan | EP300 | TOP1MT | 2 | |||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | EP300 | TOP1MT | 2 | |||||||
| asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine | EP300 | TOP1MT | 2 | |||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | EP300 | KIT | 2 | |||||||
| biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging | EP300 | TLR9 | 2 | |||||||
| bortezomib | EP300 | PSMB5 | 2 | |||||||
| bryostatin 1, paclitaxel | EP300 | PRKCE | 2 | |||||||
| cabozantinib | EP300 | RET | 2 | |||||||
| cabozantinib, atezolizumab, cabozantinib, cabozantinib | EP300 | RET | 2 | |||||||
| carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy | EP300 | CA3 | 2 | |||||||
| cetuximab, cisplatin, irinotecan, radiation therapy, surgery | EP300 | TOP1MT | 2 | |||||||
| cpt- 11, cisplatin, celecoxib, radiation, surgery | EP300 | CA3 | 2 | |||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | EP300 | ALK | 2 | |||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | EP300 | RET | 2 | |||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | EP300 | HDAC3 | 2 | |||||||
| gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a | EP300 | RET | 2 | |||||||
| gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a | EP300 | KIT | 2 | |||||||
| inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide | EP300 | TOP1MT | 2 | |||||||
| irinotecan, capecitabine | EP300 | TOP1MT | 2 | |||||||
| irinotecan, docetaxel | EP300 | TOP1MT | 2 | |||||||
| lenvatinib, pembrolizumab | EP300 | RET | 2 | |||||||
| lenvatinib, pembrolizumab | EP300 | KIT | 2 | |||||||
| lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate | EP300 | RET | 2 | |||||||
| lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate | EP300 | KIT | 2 | |||||||
| ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab | EP300 | TOP1MT | 2 | |||||||
| melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells | EP300 | CHRNB4 | 2 | |||||||
| mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a | EP300 | RET | 2 | |||||||
| mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a | EP300 | KIT | 2 | |||||||
| pembrolizumab, guadecitabine, mocetinostat | EP300 | HDAC3 | 2 | |||||||
| pembrolizumab, lenvatinib | EP300 | RET | 2 | |||||||
| pembrolizumab, lenvatinib | EP300 | KIT | 2 | |||||||
| pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu | EP300 | RET | 2 | |||||||
| pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu | EP300 | KIT | 2 | |||||||
| pembrolizumab, paclitaxel, docetaxel, irinotecan | EP300 | TOP1MT | 2 | |||||||
| pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin | EP300 | RET | 2 | |||||||
| pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin | EP300 | KIT | 2 | |||||||
| quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery | EP300 | RET | 2 | |||||||
| regorafenib, laboratory biomarker analysis | EP300 | RET | 2 | |||||||
| regorafenib, laboratory biomarker analysis | EP300 | KIT | 2 | |||||||
| sorafenib, administered orally, ct/mri | EP300 | RET | 2 | |||||||
| sorafenib, administered orally, ct/mri | EP300 | KIT | 2 | |||||||
| topotecan | EP300 | TOP1MT | 2 | |||||||
| carfilzomib | EP300 | PSMB5 | 7 | |||||||
| rosuvastatin | EP300 | HMGCR | 7 | |||||||
| selpercatinib | EP300 | RET | 7 | |||||||
| sorafenib | EP300 | RET | 7 | |||||||
| sorafenib | EP300 | KIT | 7 | |||||||
| vandetanib | EP300 | RET | 7 | |||||||
| 3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat | EP300 | HDAC3 | 1 | |||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy (imrt), temozolomide, chloroquine, tumor treating fields therapy (ttf) | EP300 | TLR9 | 1 | |||||||
| 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat | EP300 | HDAC3 | 1 | |||||||
| 5 fluorouracil, leucovorin, irinotecan, oxaliplatin | EP300 | TOP1MT | 1 | |||||||
| 9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan | EP300 | TOP1MT | 1 | |||||||
| abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf | EP300 | TOP1MT | 1 | |||||||
| acetazolamide, temozolomide | EP300 | CA14 | 1 | |||||||
| acetazolamide, temozolomide | EP300 | CA3 | 1 | |||||||
| actidose aqua, artesunate, amodiaquine | EP300 | HNMT | 1 | |||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | EP300 | KIT | 1 | |||||||
| afatinib, irinotecan | EP300 | TOP1MT | 1 | |||||||
| aldoxorubicin, topotecan | EP300 | TOP1MT | 1 | |||||||
| alvocidib, docetaxel | EP300 | CDK9 | 1 | |||||||
| alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis | EP300 | CDK9 | 1 | |||||||
| aminolevulinic acid | EP300 | ALAD | 1 | |||||||
| aminolevulinic acid, surgical resection | EP300 | ALAD | 1 | |||||||
| amrubicin, topotecan | EP300 | TOP1MT | 1 | |||||||
| andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel | EP300 | TOP1MT | 1 | |||||||
| apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib | EP300 | ALK | 1 | |||||||
| ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine | EP300 | EGLN3 | 1 | |||||||
| at-101, topotecan | EP300 | TOP1MT | 1 | |||||||
| atezolizumab, cabozantinib | EP300 | RET | 1 | |||||||
| atezolizumab, tivozanib | EP300 | KIT | 1 | |||||||
| atorvastatin, temozolomide, radiotherapy | EP300 | NR1I3 | 1 | |||||||
| atorvastatin, temozolomide, radiotherapy | EP300 | HMGCR | 1 | |||||||
| avapritinib, midazolam | EP300 | KIT | 1 | |||||||
| avastin, bortezomib | EP300 | PSMB5 | 1 | |||||||
| avastin, temozolomide, irinotecan | EP300 | TOP1MT | 1 | |||||||
| avastin, temozolomide, radiation therapy (xrt), irinotecan | EP300 | TOP1MT | 1 | |||||||
| avelumab, irinotecan, paclitaxel, best supportive care (bsc) | EP300 | TOP1MT | 1 | |||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | EP300 | HDAC3 | 1 | |||||||
| azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine | EP300 | TOP1MT | 1 | |||||||
| bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 | EP300 | TOP1MT | 1 | |||||||
| bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil | EP300 | TOP1MT | 1 | |||||||
| berzosertib, computed tomography assisted biopsy, endoscopic biopsy, irinotecan, magnetic resonance imaging | EP300 | TOP1MT | 1 | |||||||
| bevacizumab [avastin], irinotecan, temozolomide | EP300 | TOP1MT | 1 | |||||||
| bevacizumab, dasatinib, placebo | EP300 | KIT | 1 | |||||||
| bevacizumab, irinotecan | EP300 | TOP1MT | 1 | |||||||
| bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging | EP300 | TOP1MT | 1 | |||||||
| bevacizumab, temozolomide, radiation therapy (xrt), topotecan | EP300 | TOP1MT | 1 | |||||||
| bevacizumab, temozolomide, vorinostat | EP300 | HDAC3 | 1 | |||||||
| bi 764532, topotecan, single agent chemotherapy | EP300 | TOP1MT | 1 | |||||||
| binimetinib, hydroxychloroquine | EP300 | TLR9 | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib | EP300 | KIT | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, endoscopic ultrasound, fluorouracil, irinotecan, leucovorin, lymph node biopsy, magnetic resonance imaging, oxaliplatin, pembrolizumab, photodynamic therapy, positron emission tomography, questionnaire administration, verteporfin | EP300 | TOP1MT | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging | EP300 | RET | 1 | |||||||
| biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging | EP300 | KIT | 1 | |||||||
| biopsy, biospecimen collection, crizotinib, radiologic examination | EP300 | ALK | 1 | |||||||
| biospecimen collection, computed tomography, core biopsy, fluorouracil, irinotecan, leucovorin, leucovorin calcium, oxaliplatin, quemliclustat, zimberelimab | EP300 | TOP1MT | 1 | |||||||
| biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography | EP300 | RET | 1 | |||||||
| biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography | EP300 | KIT | 1 | |||||||
| bl-b01d1, irinotecan, paclitaxel, docetaxel | EP300 | TOP1MT | 1 | |||||||
| bl-b01d1, topotecan | EP300 | TOP1MT | 1 | |||||||
| bnt327 dose level 1 (dl1), bnt327 dose level 2 (dl2), etoposide, carboplatin, paclitaxel, topotecan | EP300 | TOP1MT | 1 | |||||||
| bortezomib, carboplatin, paclitaxel | EP300 | PSMB5 | 1 | |||||||
| bortezomib, gemcitabine hydrochloride | EP300 | PSMB5 | 1 | |||||||
| bortezomib, irinotecan | EP300 | TOP1MT | 1 | |||||||
| bortezomib, irinotecan | EP300 | PSMB5 | 1 | |||||||
| bortezomib, radiation therapy | EP300 | PSMB5 | 1 | |||||||
| bortezomib, temozolomide, pharmacological study | EP300 | PSMB5 | 1 | |||||||
| botensilimab, balstilimab, chloroquine phosphate, celecoxib | EP300 | CA3 | 1 | |||||||
| cabozantinib, durvalumab, tremelimumab | EP300 | RET | 1 | |||||||
| cabozantinib, nivolumab | EP300 | RET | 1 | |||||||
| cabozantinib, pembrolizumab | EP300 | RET | 1 | |||||||
| camrelizumab, docetaxel, irinotecan | EP300 | TOP1MT | 1 | |||||||
| camrelizumab, irinotecan, paclitaxel, paclitaxel-albumin, docetaxel, anlotinib | EP300 | TOP1MT | 1 | |||||||
| capecitabine, oxaliplatin, irinotecan | EP300 | TOP1MT | 1 | |||||||
| capecitabine, vorinostat, radiotherapy, surgery to remove tumor | EP300 | HDAC3 | 1 | |||||||
| carboplatin, irinotecan | EP300 | TOP1MT | 1 | |||||||
| carboxylesterase-expressing allogeneic neural stem cells, irinotecan, irinotecan hydrochloride, laboratory biomarker analysis, pharmacological study | EP300 | TOP1MT | 1 | |||||||
| ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin | EP300 | TP53 | 1 | |||||||
| celecoxib, cyclophosphamide, etoposide, thalidomide | EP300 | CA3 | 1 | |||||||
| celecoxib, isotretinoin, temozolomide, thalidomide | EP300 | CA3 | 1 | |||||||
| celecoxib, temozolomide, thalidomide, adjuvant therapy | EP300 | CA3 | 1 | |||||||
| ceritinib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis, paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study | EP300 | ALK | 1 | |||||||
| cetuximab, bevacizumab, irinotecan | EP300 | TOP1MT | 1 | |||||||
| cetuximab, bortezomib | EP300 | PSMB5 | 1 | |||||||
| cetuximab, irinotecan, oxaliplatin, uft | EP300 | TOP1MT | 1 | |||||||
| chloroquine | EP300 | TLR9 | 1 | |||||||
| chloroquine, radiotherapy, temozolomide | EP300 | TLR9 | 1 | |||||||
| cisplatin, fluorouracil, gemcitabine, irinotecan, leucovorin, nab-paclitaxel, oxaliplatin, radiation therapy | EP300 | TOP1MT | 1 | |||||||
| cisplatin, gleevec™, irinotecan | EP300 | TOP1MT | 1 | |||||||
| cisplatin, irinotecan, capecitabine | EP300 | TOP1MT | 1 | |||||||
| cisplatin, pemetrexed disodium, sorafenib | EP300 | RET | 1 | |||||||
| cisplatin, pemetrexed disodium, sorafenib | EP300 | KIT | 1 | |||||||
| cobimetinib, hydroxychloroquine, atezolizumab | EP300 | TLR9 | 1 | |||||||
| cyproheptadine hydrochloride, megestrol acetate | EP300 | PGR | 1 | |||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | EP300 | KIT | 1 | |||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | EP300 | KIT | 1 | |||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | EP300 | KIT | 1 | |||||||
| dasatinib, mfolfox6 | EP300 | KIT | 1 | |||||||
| dasatinib, pharmacological study | EP300 | KIT | 1 | |||||||
| dasatinib, temozolomide, placebo, radiation therapy | EP300 | KIT | 1 | |||||||
| digoxin, 5fluorouracil, calcium leucovorin, irinotecan, oxaliplatin | EP300 | TOP1MT | 1 | |||||||
| durvalumab, oxaliplatin, irinotecan, calcium folinate (leucovorin), fluorouracil, pegylated g-csf | EP300 | TOP1MT | 1 | |||||||
| endoscopic variceal ligation, carvedilol | EP300 | SELE | 1 | |||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | EP300 | CHEK1 | 1 | |||||||
| enzastaurin, lomustine | EP300 | CHEK1 | 1 | |||||||
| enzastaurin, temozolomide, radiation therapy | EP300 | CHEK1 | 1 | |||||||
| eras-007, encorafenib, cetuximab, palbociclib | EP300 | MAPK8 | 1 | |||||||
| eras-007, encorafenib, cetuximab, palbociclib | EP300 | LIMK2 | 1 | |||||||
| erdafitinib | EP300 | RET | 1 | |||||||
| erdafitinib | EP300 | KIT | 1 | |||||||
| ethanol, enoxaparin | EP300 | CHRNB4 | 1 | |||||||
| etomidate, midazolam, meperidine | EP300 | GRIN2C | 1 | |||||||
| etomidate, midazolam, meperidine | EP300 | GRIN2B | 1 | |||||||
| everolimus, sorafenib | EP300 | RET | 1 | |||||||
| everolimus, sorafenib | EP300 | KIT | 1 | |||||||
| fluorouracil, irinotecan, irinotecan hydrochloride, leucovorin, leucovorin calcium, nivolumab, oxaliplatin, therapeutic conventional surgery | EP300 | TOP1MT | 1 | |||||||
| fluorouracil, leucovorin calcium, oxaliplatin, irinotecan, nivolumab, magnetic resonance imaging, computed tomography, biospecimen collection, questionnaire administration | EP300 | TOP1MT | 1 | |||||||
| fluorouracil, oxaliplatin, irinotecan | EP300 | TOP1MT | 1 | |||||||
| gemcitabine, abraxane, hydroxychloroquine | EP300 | TLR9 | 1 | |||||||
| gemcitabine, erlotinib, sorafenib | EP300 | RET | 1 | |||||||
| gemcitabine, erlotinib, sorafenib | EP300 | KIT | 1 | |||||||
| gemcitabine, hydroxychloroquine, nab-paclitaxel, paricalcitol | EP300 | TLR9 | 1 | |||||||
| gemcitabine, nab-paclitaxel, irinotecan, intensity-modulated radiation therapy (imrt) | EP300 | TOP1MT | 1 | |||||||
| gemcitabine, oxaliplatin, imatinib | EP300 | RET | 1 | |||||||
| gemcitabine, oxaliplatin, imatinib | EP300 | KIT | 1 | |||||||
| gemcitabine, placebo, sorafenib | EP300 | RET | 1 | |||||||
| gemcitabine, placebo, sorafenib | EP300 | KIT | 1 | |||||||
| gemcitabine, sorafenib, radiotherapy | EP300 | RET | 1 | |||||||
| gemcitabine, sorafenib, radiotherapy | EP300 | KIT | 1 | |||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | EP300 | HDAC3 | 1 | |||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | EP300 | RET | 1 | |||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | EP300 | KIT | 1 | |||||||
| gemcitabine, sunitinib | EP300 | KIT | 1 | |||||||
| gemcitabine, taxotere, xeloda, cisplatin, irinotecan | EP300 | TOP1MT | 1 | |||||||
| genistein, erlotinib hydrochloride, gemcitabine hydrochloride | EP300 | ESRRA | 1 | |||||||
| h101, tislelizumab, lenvatinib | EP300 | RET | 1 | |||||||
| h101, tislelizumab, lenvatinib | EP300 | KIT | 1 |